Vivos Therapeutics Inc (VVOS) Long-Term Liabilities to Equity

Vivos Therapeutics pricing policy relies on FDA approval and insurance company support. The business is currently scaling b2b sales of CARE systems to dentists to capture the niche. The long-term debt-to-equity structure reflects the market consensus, with the indicator standing at 0.00. Stable demand for apnea therapy makes the company a defensive asset, independent of economic fluctuations.

Vivos Therapeutics (VVOS) is scaling sales of medical devices for apnea therapy, leveraging its patent protection. The trend in the ratio of long-term debt to net assets reflects the share of borrowed capital with a maturity of over one year within the equity structure. An increase in this metric signals rising financial leverage, while a downward curve confirms high business autonomy. This determines the overall cost of capital and the company's stability.